CSS
PTGX icon

Cubist Systematic Strategies’s Protagonist Therapeutics PTGX Stock Holding History

Cubist Systematic Strategies’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-84,202
Closed -$2.92M – 3395
2024
Q2 		$2.92M Buy
84,202
+78,207
+1,305% +$2.29M 0.02% 1095
2024
Q1 		$173K Buy
+5,995
New +$163K ﹤0.01% 3136
2023
Q2 		– Sell
-64,978
Closed -$1.49M – 4150
2023
Q1 		$1.49M Buy
64,978
+13,472
+26% +$226K 0.01% 1867
2022
Q4 		$562K Buy
51,506
+32,477
+171% +$274K ﹤0.01% 2936
2022
Q3 		$160K Hold
19,029
– – ﹤0.01% 3857
2022
Q2 		$151K Sell
19,029
-9,107
-32% -$110K ﹤0.01% 3816
2022
Q1 		$666K Buy
28,136
+27,590
+5,053% +$777K 0.01% 2346
2021
Q4 		$19K Sell
546
-571
-51% -$18K ﹤0.01% 3378
2021
Q3 		$20K Sell
1,117
-2,783
-71% -$119K ﹤0.01% 2887
2021
Q2 		$175K Sell
3,900
-10,800
-73% -$356K ﹤0.01% 2607
2021
Q1 		$381K Buy
+14,700
New +$372K ﹤0.01% 2109
2020
Q3 		– Sell
-22,085
Closed -$390K – 2607
2020
Q2 		$390K Buy
+22,085
New +$277K 0.01% 1713
2019
Q4 		– Sell
-21,992
Closed -$264K – 2518
2019
Q3 		$264K Buy
+21,992
New +$277K 0.01% 1616
2018
Q2 		– Sell
-11,593
Closed -$100K – 1992
2018
Q1 		$100K Buy
11,593
+8,327
+255% +$157K 0.01% 1590
2017
Q4 		$68K Buy
+3,266
New +$57.9K ﹤0.01% 1747

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cubist Systematic Strategies's PTGX Position: Q3 2024 in Review

Cubist Systematic Strategies sold out of Protagonist Therapeutics (PTGX) in Q3 2024, closing a stake of 84,202 shares — an estimated $2.92M sold.

Cubist Systematic Strategies first reported a position in PTGX in Q4 2017 and held it in 15 quarters. The position peaked at $2.92M in Q2 2024. 240 funds tracked by Wall St. Rank hold PTGX as of Q3 2024.

  • Cubist Systematic Strategies reported no remaining Protagonist Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 84,202 Protagonist Therapeutics shares in Q3 2024, an estimated $2.92M.
  • Cubist Systematic Strategies first reported a position in Protagonist Therapeutics in Q4 2017 and held it in 15 quarters.
  • Cubist Systematic Strategies's Protagonist Therapeutics position peaked at $2.92M in Q2 2024.
  • 240 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2024.

Based on Cubist Systematic Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.